Grant received in 2024

DCCC has funded 200,000 DKK to the project.

Women with metastatic breast cancer whose tumours have a mismatch between their genomic profile and immunohistochemical expression of the estrogen-receptor fare worse than patients with a match and can expect a diminished treatment efficacy with standard treatment.

This trial will investigate the optimal treatment for patients with a mismatch between their genomic profile and immunohistochemical subtype in 1st line metastatic breast cancer to potentially improve the outcomes for these patients The initiative will conduct a multicentre, open-label, randomised controlled trial. All oncological departments who treat patients with metastatic breast cancer can participate. The objective of this trial will be to evaluate the effect of trastuzumab-deruxtecan versus standard of care on progression-free survival (PFS).

The DCCC funding will be used to support key preparations for the study, including protocol development, submission to the European Medicines Agency (EMA), meetings with Scandinavian partners, and preparation of grant applications.

Multidisciplinary organisation
The study is anchored in the Danish Breast Cancer Group (DBCG).

Project stakeholder

• Anne-Vibeke Lænkholm, Consultant, Department of Pathology, Zealand University Hospital, Roskilde
• Ann Knop, Consultant, Department of Oncology, Rigshospitalet
• Bent Ejlertsen, Consultant, Department of Oncology, Rigshospitalet
• Maj-Britt Raaby Jensen, Chief Statistician, DBCG, Department of Oncology, Rigshospitalet

Medical Council DBCG

• Tobias Berg, MD, Department of Oncology, Rigshospitalet. Primary contact, mail: berg.01@regionh.dk
• Eva Brix, Consultant, Department of Oncology, Herlev Hospital
• Hella Danø, Consultant, Department of Oncology, North Zealand Hospital
• Vesna Glavicic, Consultant, Department of Oncology, Næstved Hospital
• Jeanette Roenlev, Consultant, Department of Oncology, Odense University Hospital
• Lone Volmer, Consultant, Department of Oncology, Vejle Hospital
• Erik Hugger Jakobsen, Consultant, Department of Oncology, Sønderborg
• Hanne Nielsen, Consultant, Department of Oncology, Aarhus University Hospital
• Julia Kenholm, Consultant, Department of Oncology, Gødstrup
• Sophie Yammeni, Consultant, Department of Oncology, Aalborg University Hospital